Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Small Cell Lung Cancer Recurrent × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 344 Brain Neoplasms 133 Glioma 131 Gliosarcoma 118 Astrocytoma 97 Central Nervous System Neoplasms 93 Oligodendroglioma 64 Melanoma 59 Neuroblastoma 37 Medulloblastoma 28 Neoplasms 25 Recurrence 24 Neoplasm Metastasis 23 Ependymoma 23 Sarcoma, Ewing 19 Sarcoma 17 Rhabdomyosarcoma 15 Diffuse Intrinsic Pontine Glioma 15 Ovarian Neoplasms 13 Breast Neoplasms 13 Lymphoma 12 Neuroendocrine Tumors 11 Lung Neoplasms 10 Choroid Plexus Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Small Cell Lung Carcinoma 9 Osteosarcoma 9 Neuroectodermal Tumors, Primitive 9 Optic Nerve Glioma 8 Neuroectodermal Tumors, Primitive, Peripheral 8

Interventions

atezolizumab 1 Temozolomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02477813 2018-11-13

TeRes

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated

Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡